[Prediction of unplanned discontinuation of treatment in patients with castration-resistant prostate cancer-results from the IBuTu study]

Urologe A. 2018 Aug;57(8):909-918. doi: 10.1007/s00120-018-0704-5.
[Article in German]
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Forecasting*
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Risk Factors
  • Withholding Treatment*

Substances

  • Prostate-Specific Antigen